生长激素治疗不增加颅咽管瘤及无功能垂体腺瘤复发风险
回顾性观察研究纳入1995至2018年间283例因无功能垂体腺瘤或颅咽管瘤导致成人生长激素缺乏症的患者,其中123例接受标准剂量重组人生长激素替代治疗,160例为对照。单因素分析显示治疗组肿瘤复发率19.5%低于对照组29.7%(HR 0.53,95%CI 0.32-0.86,P=0.01),但多因素Cox分析中重组人生长激素治疗与复发风险无显著关联(HR 0.82,95%CI 0.47-1.44,P=0.50)。结论认为重组人生长激素替代治疗不增加此类患者的肿瘤复发风险。
要点
- 单因素分析中重组人生长激素治疗组肿瘤复发率19.5%低于对照组29.7%(HR 0.53,95%CI 0.32-0.86,P=0.01)。
- 多因素Cox分析显示复发风险与基线MRI检出残留病灶(HR 9.17,95%CI 4.88-17.22,P<0.001)和未行放疗(HR 16.97,95%CI 7.55-38.16,P<0.001)相关。
- 多因素分析中重组人生长激素治疗与复发风险无显著关联(HR 0.82,95%CI 0.47-1.44,P=0.50)。
核心结论
- 在因无功能垂体腺瘤或颅咽管瘤导致成人生长激素缺乏症的患者中,重组人生长激素替代治疗与肿瘤复发风险无关联。
- 这些数据进一步支持重组人生长激素治疗对垂体肿瘤复发具有中性作用的证据。
研究设计与样本
- 回顾性观察性研究,纳入1995年至2018年间连续283例因无功能垂体腺瘤或颅咽管瘤导致成人生长激素缺乏症的患者。
- 123例(43.5%)接受标准剂量重组人生长激素治疗,其余160例为对照。
主要发现
- 单因素分析中,重组人生长激素治疗组肿瘤复发频率(19.5%)低于对照组(29.7%;HR 0.53,95%CI 0.32-0.86;P=0.01)。
- 多因素Cox分析显示,肿瘤复发风险与基线磁共振成像检出残留病灶相关(HR 9.17;95%CI 4.88-17.22;P<0.001),与未行放疗相关(HR 16.97;95%CI 7.55-38.16;P<0.001)。
- 多因素分析中,重组人生长激素治疗与较低的复发风险不再相关(HR 0.82;95%CI 0.47-1.44;P=0.50)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Recombinant human growth hormone (rhGH) replacement therapy is often prescribed in patients with nonfunctioning pituitary adenoma (NFPA) or craniopharyngioma. OBJECTIVE: To study whether rhGH therapy in patients with adult growth hormone deficiency (AGHD) increases the risk of pituitary tumor recurrence. DESIGN: Retrospective, observational study. SETTING: Tertiary care center. PATIENTS: We studied 283 consecutive patients with AGHD due to NFPA or craniopharyngioma between 1995 and 2018. INTERVENTION: rhGH treatment at standard doses was initiated in 123 patients (43.5%). The remaining 160 patients served as controls. MAIN OUTCOME MEASURE: Risk of tumor recurrence in rhGH-treated and control patients. RESULTS: In univariate analysis, recurrence of the pituitary tumor was less frequent in rhGH-treated patients (19.5%) than in controls (29.7%; hazard ratio [HR] 0.53, 95% confidence interval [CI] 0.32-0.86; P = .01). Multivariate Cox analysis demonstrated that the risk of tumor recurrence was associated with detection of residual disease at the baseline magnetic resonance imaging (HR 9.17; 95% CI, 4.88-17.22; P < .001) and not having performed radiotherapy (HR 16.97; 95% CI, 7.55-38.16; P < .001), while rhGH treatment was no longer associated with a lower risk of recurrence (HR 0.82; 95% CI, 0.47-1.44; P = .50). CONCLUSIONS: We found no association between rhGH replacement and the risk of tumor recurrence in patients with AGHD caused by NFPA or craniopharyngioma. These data add to the mounting evidence that rhGH therapy has a neutral effect on the recurrence of pituitary tumors. PRÉCIS: Replacement therapy with rhGH is prescribed to patients with adult growth hormone deficiency. Our study found no increased risk of pituitary tumor recurrence.
引用
- Losa M, Castellino L, Pagnano A, et al. Growth Hormone Therapy Does Not Increase the Risk of Craniopharyngioma and Nonfunctioning Pituitary Adenoma Recurrence. J Clin Endocrinol Metab. 2020. PMID: 32112101. doi:10.1210/clinem/dgaa089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。